Home » Stocks » Vaccinex

Vaccinex, Inc. (VCNX)

Stock Price: $2.06 USD 0.08 (4.04%)
Updated Oct 19, 2020 4:00 PM EDT - Market closed
Pre-market: $2.09 +0.03 (1.46%) Oct 20, 8:13 AM

Stock Price Chart

Key Info

Market Cap 41.24M
Revenue (ttm) 404,000
Net Income (ttm) -27.62M
Shares Out 20.02M
EPS (ttm) -1.80
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 19, 2020
Last Price $2.06
Previous Close $1.98
Change ($) 0.08
Change (%) 4.04%
Day's Open 2.02
Day's Range 1.98 - 2.12
Day's Volume 43,353
52-Week Range 1.63 - 12.23

More Stats

Market Cap 41.24M
Enterprise Value 41.84M
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 20.02M
Float 6.53M
EPS (basic) -1.78
EPS (diluted) -1.80
FCF / Share -1.77
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 762,776
Short Ratio 0.50
Short % of Float 11.69%
Beta 1.83
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 102.07
PB Ratio n/a
Revenue 404,000
Operating Income -27.68M
Net Income -27.62M
Free Cash Flow -29.52M
Net Cash -608,000
Net Cash / Share -0.03
Gross Margin 80.20%
Operating Margin -6,850.50%
Profit Margin -6,836.10%
FCF Margin -7,305.94%
ROA -338.50%
ROE -1,303.09%
ROIC 621.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 1
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

Current: $2.06
Target: 7.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-27.76%704.44%-71.52%-
Gross Profit0.32-0.31-0.070.20
Operating Income-32.02-27.28-21.10-20.26
Net Income-31.86-29.52-18.72-13.94
Shares Outstanding12.885.221.101.04
Earnings Per Share-2.47-5.65-19.90-25.27
Operating Cash Flow-30.72-25.28-21.39-19.72
Capital Expenditures-0.08-0.24-0.07-0.79
Free Cash Flow-30.79-25.51-21.46-20.51
Cash & Equivalents2.7819.724.181.66
Total Debt--2.811.04
Net Cash / Debt2.7819.721.370.62
Book Value-26.24-8.62-125-107
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Vaccinex, Inc.
Country United States
Employees 45
CEO Maurice Zauderer

Stock Information

Ticker Symbol VCNX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: VCNX


Vaccinex, a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), Huntington's disease, osteosarcoma, melanoma, and Alzheimer's disease. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and potentially for other autoimmune disorders; and VX25, a bi-specific natural killer T (NKT) cell stimulator, for the therapeutic application of NKT cell stimulation for cancer immunotherapy. It has a clinical trial collaboration and supply agreement with Merck KGaA to test pepinemab in combination with avelumab checkpoint inhibitor in NSCLC patients. Vaccinex, Inc. was founded in 2001 and is headquartered in Rochester, New York.